Joint Attention Processing in Social Threat Scenarios

The Proactive and Joint Attention Processing Characteristics of Children With Autism Induced by Social Threat Scenarios

This study set up two experiments using the free viewing video paradigm. By setting up social threat scenarios induced by humans (Experiment 1) and non social threat scenarios induced by objects (Experiment 2), combined with eye tracking and fNIRS technology, we explored the eye movement patterns and related brain activation characteristics of IJA in children with ASD.

Study Overview

Status

Completed

Study Type

Observational

Enrollment (Actual)

56

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Sichuan
      • Chengdu, Sichuan, China, 611731
        • School of Foreign Languages, University of Electronic Science and Technology of China

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

Yes

Sampling Method

Non-Probability Sample

Study Population

Population composition: TD and ASD. TD: 3-10 years old, with normal vision and corrected vision, hearing, and no social or behavioral problems. ASD: 3-10 years old, diagnosed by a doctor with ASD, normal vision and corrected vision, hearing, etc., but with social and behavioral problems.

Key demographic information: 3-10 years old. TD: 22 males and 6 females. ASD: 24 males and 4 females.

Source and final scale: TD recruited 36 children from Jinhua Primary School and First Kindergarten in Shehong City, Sichuan Province, and ultimately used 28 children. ASD: 52 children from special schools and rehabilitation institutions in some districts and counties of Chengdu were recruited, and 28 were ultimately used.

Description

Inclusion Criteria:

-

For ASD group:

  1. 3 years ≤ age ≤ 10 years;
  2. a diagnosis of autism spectrum disorder based on clinical symptoms, confirmed using the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and other auxiliary diagnostic scales, including the Autism Diagnostic Interview-Revised (ADI-R) and the Childhood Autism Rating Scale (CARS);
  3. further confirmation of ASD symptoms by experimenters with established research reliability using the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2), with severity scores reported;
  4. absence of comorbid physical diseases or other psychiatric disorders, including normal vision (or corrected-to-normal vision) and normal hearing;
  5. no receipt of medication, transcranial magnetic stimulation (TMS), or transcranial direct current stimulation (tDCS) within the past three months.

For TD group:The inclusion criterion for the TD group was a score below the cutoff on the Social Responsiveness Scale (SRS).

Exclusion Criteria:

-

For ASD group:

  1. age < 3 years or > 10 years;
  2. absence of a diagnosis of autism spectrum disorder based on the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) and other auxiliary diagnostic scales, including the Autism Diagnostic Interview-Revised (ADI-R) and the Childhood Autism Rating Scale (CARS);
  3. failure to meet diagnostic criteria after confirmation of ASD symptoms by experimenters with established research reliability using the Autism Diagnostic Observation Schedule, Second Edition (ADOS-2);
  4. presence of comorbid physical diseases or other psychiatric disorders, or problems with vision (or corrected-to-normal vision) and hearing;
  5. receipt of medication, transcranial magnetic stimulation (TMS), or transcranial direct current stimulation (tDCS) within the past three months.

For TD group:

children were excluded if their scores on the Social Responsiveness Scale (SRS) exceeded the cutoff.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Autism Spectrum Disorder (ASD) Group
Typically Developing Children (TD) Group

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Gaze transitions
Time Frame: The two time windows of 48-56 seconds and 70-80 seconds.
the number of transitions between face stimuli and unexpected stimuli
The two time windows of 48-56 seconds and 70-80 seconds.
The proportion of fixation time
Time Frame: The two time windows of 48-56 seconds and 70-80 seconds.
The proportion of fixation time on AOI is calculated as the fixation time on AOI divided by the total valid fixation time on the screen within each phase
The two time windows of 48-56 seconds and 70-80 seconds.
Activation concentration
Time Frame: The two time windows of 48-56 seconds and 70-80 seconds.
the concentration of cortical activation during video viewing
The two time windows of 48-56 seconds and 70-80 seconds.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 29, 2024

Primary Completion (Actual)

June 4, 2025

Study Completion (Actual)

July 1, 2025

Study Registration Dates

First Submitted

May 6, 2026

First Submitted That Met QC Criteria

May 6, 2026

First Posted (Actual)

May 13, 2026

Study Record Updates

Last Update Posted (Actual)

May 13, 2026

Last Update Submitted That Met QC Criteria

May 6, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe